SY’s financials over recent quarters reveal increasing revenues with a CAGR of roughly 10% but persistent net losses averaging around -10% to -20% net margin. Operating expenses outpace revenue growth, leading to negative operating income each quarter. A substantial non-cash impairment in prior periods further exacerbates losses. EBITDA remains negative, signaling ongoing operational cash burn.

Revenue growth has improved sequentially from approximately CNY 430 million in Q1 2026 to CNY 504 million in Q2 2026, supported by increasing user base and service demand. However, the revenue size remains insufficient to offset operating costs effectively. Cost of revenue remains stable around 55-60% of revenues, indicating consistent gross margin pressure from content acquisition and platform maintenance.

Gross margins fluctuate between 42% and 61%, with recent pressures as more commissions and platform fees reduce profitability. Operating and net margins remain deeply negative, with operating losses widening to nearly -22% in FY2025 but showing signs of contraction in 2026. High SG&A expenses, largely fixed due to platform and marketing investments, dampen profits.

Earnings are impacted heavily by non-operating items including impairments and interest income, which somewhat offset operating losses but do not represent sustainable profit sources. The quality of earnings is weakened by recurring operational losses, limited EBITDA positive periods, and lack of significant positive free cash flow.

SY’s revenue demonstrated a year-over-year increase of approximately 5-7% in recent quarters, with Q2 2026 revenues up about 17% compared to Q2 2025 (CNY 504 million vs. CNY 379 million). This reflects gradual adoption of its platform but at a slow pace relative to industry potential.

EPS remains negative but the rate of loss is moderating; EPS improved from -CNY 0.37 in Q1 2026 to -CNY 0.17 in Q2 2026, indicating sequential earnings recovery although still negative. The net income trajectory aligns with narrowing operating losses.

Growth is driven primarily by expanding user adoption and increased service transactions in key medical aesthetic areas, supported by digital marketing and platform enhancements. The company’s AI and data capabilities may offer future growth catalysts.

Growth is mostly organic with no recent acquisitive activities noted in filings. However, sustainability is challenged by competitive pressures and continuing need for investment in technology and market expansion, implying growth will require disciplined cost control.

Gross margin has declined from approximately 61% in Q3 2024 to about 44% in Q2 2026, suggesting increasing cost pressure. Operating margin remains negative, worsening in 2025 to about -17% but improving in 2026 to near -9%, signaling initial improvement. Net margin remains negative, though trending closer to breakeven with a recent ratio near -4%.

ROE and ROA are significantly negative, reflecting sustained losses and lack of asset base income. With net income ratio hovering near -16% annually, these returns remain depressed and below industry averages, indicating weak capital efficiency.

Current margin improvements depend on controlling operating expenses and scaling revenues more efficiently. Continued marketing spend and innovation investments could weigh on long-term margin sustainability unless balanced by gains in revenue scale and customer monetization.